• NEWS & PRESS
  • pressReleases
  • newsMedia
  • CAREERS
  • Career Openings
  • CONTACT US
  • WE DISCOVER AND DEVELOP NOVEL,

    DIFFERENTIATED THERAPIES IN CANCER AND BEYOND

    ADDRESS UNMET MEDICAL NEEDS FOR PATIENTS IN CHINA AND GLOBALLY

    Founded in 2016, we have established a robust in-house R&D engine underpinned by an oustanding discovery team and multi-dimensional discovery platform. We have strategically designed and developed a rich pipeline of 14 small molecule programs focused on oncology.

    01---
    02---

    Founders

    -------------------------------------------------

    Our exceptional discovery capability is driven by the experienced and visionary founds with a prolific track record of drug discovery, who have made contributions to over 50 discovery programs.

    Dr. Yao-Chang Xu
    Founder & CEO
    Dr. Yao-Chang Xu
    Founder & CEO
    Dr. Yao-Chang Xu has more than 25 years of drug dis...
    Dr. Hongping Yu
    Senior VP and co-founder, Head of Chemistry
    Dr. Hongping Yu
    Senior VP and co-founder, Head of Chemistry
    Dr. Hongping Yu has worked in drug discovery and de...
    Dr. Zhui Chen
    Senior VP and co-founder, Head of Biology
    Dr. Zhui Chen
    Senior VP and co-founder, Head of Biology
    Dr. Zhui Chen is a seasoned biologist and drug hunt...
    We address the large oncology market in China and globally.
    Leveraging our robust in-house R&D capabilities, we have developed a rich pipeline of clinical and pre-clinical stage drug candidates

    Our mission

    -------------------------------------------------

    The discovery, Development, And Clinical Verification

    We are committed to focus on discovery of next-generation candidates with improved efficacy and safety and low risks, so that patients can benefit as soon as possible.

    We strategically focus

    small molecule precision oncology therapies & small molecule immuno-oncology therapies

    Our Pipeline

    Consists of a broad range of small-molecule
    precision-oncology and immuno-oncology product candidates

    Partnership

    Excellent cooperation model and relationship

    News & Press

    OUR VISION

    We aspire to become a leading biopharmaceutical company that discovers and develops novel, differentiated therapies in cancer and beyond, addressing critical unmet needs for patients in China and globally.

    Investors

    Since our establishment, we have completed five rounds of fund raising led by blue-chip investors. Our investor base is a testament to our capabilities and supports our future success with strong financial support and industry insights.

    Tel:(+86) 021-68912098

    E-MailL:Public@abbisko.com Bd@abbisko.com

    Copyright © 2021 All rights reserved:Abbisko Therapeautics     HuICP: 17056565-1   

    {{currentdata.name}}
    {{currentdata.post}}